Oragenics, Inc. develops novel antibiotics against infectious diseases and treatments for oral mucositis. It is developing OG716, an antibiotic product candidate, which is in nonclinical testing for healthcare-associated infections, as well as other homolog antibiotic product candidates. The company is also developing AG013, which is in Phase II clinical trial for the treatment of oral mucositis in cancer patients. Its product candidates also comprise LPT3-04, a naturally occurring chemical agent for use in weight loss; and SMaRT Replacement Therapy, a topical treatment applied to the teeth to protect against tooth decay. Oragenics, Inc. has collaboration agreements with Intrexon Corporation and its subsidiary, Intrexon Actobiotics NV to develop AG013; a license agreement with LPThera LLC to develop LPT3-04; and a license agreement Texas A&M University System for access to new homologs of the lantibiotic MU1140 and other lantibiotics. The company was formerly known as Oragen, Inc. Oragenics, Inc. was founded in 1996 and is headquartered in Tampa, Florida.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone813-286-7900
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees6
Next Earnings Date11/12/2019 (Estimated)
OptionableNot Optionable
Oragenics (NASDAQ:OGEN) Frequently Asked Questions
What is Oragenics' stock symbol?
Oragenics trades on the NASDAQ under the ticker symbol "OGEN."
How were Oragenics' earnings last quarter?
Oragenics, Inc. (NASDAQ:OGEN) posted its earnings results on Wednesday, August, 14th. The company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.07) by $0.03. View Oragenics' Earnings History.
When is Oragenics' next earnings date?
What is the consensus analysts' recommendation for Oragenics?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oragenics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Oragenics.
Has Oragenics been receiving favorable news coverage?
Media stories about OGEN stock have been trending very negative recently, according to InfoTrie Sentiment. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Oragenics earned a daily sentiment score of -3.9 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 3.0 out of 10, meaning that recent press coverage is unlikely to have an effect on the stock's share price in the near future. View News Stories for Oragenics.
Who are some of Oragenics' key competitors?
Some companies that are related to Oragenics include IntelGenx Technologies (IGX), Imugene (IMU), 4d Pharma (DDDD), Pediapharm (PDP), Ampio Pharmaceuticals (AMPE), Circassia Pharmaceuticals (CIR), Orgenesis (ORGS), Tiziana Life Sciences (TILS), Medicure (MPH), AquaBounty Technologies (AQB), Equillium (EQ), Bionomics (BNO), Covalon Technologies (COV), OptiBiotix Health (OPTI) and Mereo BioPharma Group (MPH).
What other stocks do shareholders of Oragenics own?
Who are Oragenics' key executives?
Oragenics' management team includes the folowing people:
- Dr. Alan F. Joslyn, Pres, CEO & Director (Age 60)
- Mr. Michael O. Sullivan CPA, CFO, Sec. & Treasurer (Age 63)
- Dr. Martin Handfield, Sr. VP of Discovery Research (Age 48)
- Dr. Raman Bedi, Chairman of International Scientific Advisory Board and Sr. Consultant
How do I buy shares of Oragenics?
Shares of OGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Oragenics' stock price today?
One share of OGEN stock can currently be purchased for approximately $0.43.
How big of a company is Oragenics?
What is Oragenics' official website?
How can I contact Oragenics?
The company can be reached via phone at 813-286-7900.
MarketBeat Community Rating for Oragenics (NASDAQ OGEN)
MarketBeat's community ratings are surveys of what our community members think about Oragenics and other stocks. Vote "Outperform" if you believe OGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
